These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 9059857)

  • 1. Apoptotic effects of imidazo[1,2-a]pyrazine derivatives in the human Dami cell line.
    Zurbonsen K; Michel A; Bonnet PA; Gannoun-Zaki L; Mathieu MN; Chevillard C
    Eur J Pharmacol; 1997 Feb; 320(2-3):215-21. PubMed ID: 9059857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiproliferative, differentiating and apoptotic effects elicited by imidazo[1,2-a]pyrazine derivatives.
    Zurbonsen K; Michel A; Bonnet PA; Mathieu MN; Chevillard C
    Gen Pharmacol; 1999 Jan; 32(1):135-41. PubMed ID: 9888266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiproliferative effects of imidazo[1,2-a]pyrazine derivatives on the Dami cell line.
    Zurbonsen K; Michel A; Vittet D; Bonnet PA; Chevillard C
    Biochem Pharmacol; 1997 Aug; 54(3):365-71. PubMed ID: 9278095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of the megakaryoblastic Dami cell line differentiation by phosphodiesterase inhibitors and imidazo[1,2-a]pyrazine derivatives.
    Zurbonsen K; Michel A; Vittet D; Bonnet PA; Chevillard C
    Pharmacol Toxicol; 1997 Jun; 80(6):286-9. PubMed ID: 9225365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological activities of imidazo[1,2-alpha]pyrazine derivatives.
    Michel A; Laurent F; Chapat JP; Boucard M; Bonnet PA
    Arzneimittelforschung; 1995 Dec; 45(12):1288-93. PubMed ID: 8595086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissociation between phosphodiesterase inhibition and antiproliferative effects of phosphodiesterase inhibitors on the Dami cell line.
    Zurbonsen K; Michel A; Vittet D; Bonnet PA; Chevillard C
    Biochem Pharmacol; 1997 Apr; 53(8):1141-7. PubMed ID: 9175719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and antibronchospastic activity of 8-alkoxy- and 8-(alkylamino)imidazo[1,2-a]pyrazines.
    Bonnet PA; Michel A; Laurent F; Sablayrolles C; Rechencq E; Mani JC; Boucard M; Chapat JP
    J Med Chem; 1992 Sep; 35(18):3353-8. PubMed ID: 1527785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure activity relationship studies of imidazo[1,2-a]pyrazine derivatives against cancer cell lines.
    Myadaraboina S; Alla M; Saddanapu V; Bommena VR; Addlagatta A
    Eur J Med Chem; 2010 Nov; 45(11):5208-16. PubMed ID: 20832916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of imidazo[1,2-a]pyrazine derivatives with uterine-relaxing, antibronchospastic, and cardiac-stimulating properties.
    Sablayrolles C; Cros GH; Milhavet JC; Rechenq E; Chapat JP; Boucard M; Serrano JJ; McNeill JH
    J Med Chem; 1984 Feb; 27(2):206-12. PubMed ID: 6319701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the phosphodiesterase inhibition by 2-(3-methoxy-5-methylsulfinyl-2-thienyl)-1H-imidazo-(4,5-c)-pyridine HCl and its sulfide- and sulfone derivatives in myocardial preparations from failing human hearts.
    Bethke T; Klimkiewicz A; Meyer W; Schumacher C; Schmitz W; Scholz H; Starbatty J; Wenzlaff H; Zimmermann W
    Arzneimittelforschung; 1995 Jul; 45(7):771-6. PubMed ID: 8573220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of new imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives with antiproliferative activity against melanoma cells.
    Garamvölgyi R; Dobos J; Sipos A; Boros S; Illyés E; Baska F; Kékesi L; Szabadkai I; Szántai-Kis C; Kéri G; Őrfi L
    Eur J Med Chem; 2016 Jan; 108():623-643. PubMed ID: 26724730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their nonmalignant counterparts.
    Marko D; Romanakis K; Zankl H; Fürstenberger G; Steinbauer B; Eisenbrand G
    Cell Biochem Biophys; 1998; 28(2-3):75-101. PubMed ID: 9515161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P2 purinoceptors contribute to ATP-induced inhibition of L-type Ca2+ current in rabbit atrial myocytes.
    Yamamoto T; Habuchi Y; Nishio M; Morikawa J; Tanaka H
    Cardiovasc Res; 1999 Jan; 41(1):166-74. PubMed ID: 10325964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [SCA 40 and derivatives: new bronchodilators in an imidazo(1,2-a)pyrazine series].
    Bonnet PA; Vitse O; Bénezech V; Subra G; Fabréguettes JR; Zanik L; Laurent F; Michel A; Bompart J; Chapat JP
    Ann Pharm Fr; 1998; 56(4):155-9. PubMed ID: 9770008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of phosphodiesterase inhibitors on accumulation of cyclic AMP in isolated ventricular cardiomyocytes.
    Kelso EJ; McDermott BJ; Silke B
    Biochem Pharmacol; 1995 Feb; 49(4):441-52. PubMed ID: 7872950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenosine promotes regulation of corneal hydration through cyclic adenosine monophosphate.
    Riley MV; Winkler BS; Starnes CA; Peters MI
    Invest Ophthalmol Vis Sci; 1996 Jan; 37(1):1-10. PubMed ID: 8550312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
    Seldon PM; Barnes PJ; Meja K; Giembycz MA
    Mol Pharmacol; 1995 Oct; 48(4):747-57. PubMed ID: 7476903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.
    Robarge KD; Lee W; Eigenbrot C; Ultsch M; Wiesmann C; Heald R; Price S; Hewitt J; Jackson P; Savy P; Burton B; Choo EF; Pang J; Boggs J; Yang A; Yang X; Baumgardner M
    Bioorg Med Chem Lett; 2014 Oct; 24(19):4714-4723. PubMed ID: 25193232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633.
    Cohan VL; Showell HJ; Fisher DA; Pazoles CJ; Watson JW; Turner CR; Cheng JB
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1356-61. PubMed ID: 8819523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective tracheal relaxation and phosphodiesterase-IV inhibition by xanthine derivatives.
    Miyamoto K; Kurita M; Ohmae S; Sakai R; Sanae F; Takagi K
    Eur J Pharmacol; 1994 May; 267(3):317-22. PubMed ID: 8088370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.